Welcome to Your Premier NPD Summit Community Hub
This is the global network for industry leaders to connect, collaborate, and exchange insights across neuropsychiatric drug development. Bringing together 150+ experts spanning discovery, translational research, and clinical development, this forum is dedicated to tackling real-world challenges, sharing practical learnings, and building meaningful connections across the neuropsychiatric landscape.
Networking Spotlight
Conference Day One - Morning
A prime chance to make the most of in-person networking and forge new connections as new companies enter, and existing ones broaden their presence within the psychiatric drug development space. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the summit.
Conference Day One - Afternoon
This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of preclinical, translational, and clinical scientists eager to hear the latest advancements in neuropsychiatric therapeutic development, you will have the opportunity to display a poster presenting your own work and innovations. Don’t miss out on the chance to connect, learn, and present.
Don’t Just Take Our Word For It…
The Neuropsychiatric Drug Development conference is an excellent opportunity to learn about cutting edge science and drug development in an intimate setting. It has consistently been an engaging and collaborative environment where we are able to interact with our peers who share the common goal of finding the best new therapies for patients.
Christopher Ocampo, Head of Psychiatry, Neuroscience Clinical Development, AbbVie
High quality presentations across preclinical, translational, and clinical development with both small biotech and big pharma represented. The size of the meeting made networking much easier than larger meetings.
Samuel Banister, Co‑Founder & CSO, Xylo Bio
For the challenges of neuropsychiatric drug development, this conference did an excellent job in selecting the topics for the various sessions. The short 2-day format was also well thought-out, and well-planned. Overall, it was an exhilarating 2-days, spent with folks facing similar challenges and discussing solutions and strategies to move forward to address the tremendous need for new approaches in mental health disorders.
Nurulain Zaveri, Founder & President, CSO, Astraea Therapeutics
Explore the Agenda
Dive into 2 tracks, spanning discovery – clinical development and access, 3 preconference day workshops and 35+ expert speakers shaping the future of psychiatric R&D
Partner With Us
Showcase your solutions, connect with decision makers, and position your company as the go-to provider in neuropsychiatric and neurodevelopment research
Join Biopharma Experts
Network with pharma, biotech, diagnostics, academia, consortia, and regulatory voices driving real-world adoption